Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

Duskfall Nov. 14 at 8:48 PM

Yup $CHR $VYNE $OLB

1 · Reply

Lyn30 Nov. 14 at 6:04 PM

$VYNE Analyst pt $4 with with buy rating (1) High $6 and low $2.

1 · Reply

Lyn30 Nov. 14 at 5:52 PM

$VYNE Wide range resistance imo Around 2.25 is the resistance Anytime it can violent imo Cash/sh .98

0 · Reply

Lyn30 Nov. 14 at 5:22 PM

$VYNE Market is the place of chess game Fundamentals , this that all r BS imo . It’s all about when they want 🚀🚀🚀 and whether one join before run who makes profit or after run who becomes bag holders that’s all.

0 · Reply

CashtyNashty Nov. 14 at 5:21 PM

$VYNE cool chart. 😃

0 · Reply

hiTHit Nov. 14 at 4:52 PM

$VYNE Handsome gentlemen, beautiful ladies, dear children, I am your captain pilot. Please take your seats and fasten your seat belts. Our price will exceed 1 dollar soon, but I don't want to hear your screams. Who am I? Of course, I'm the CEO of Nvidia.🤓

1 · Reply

skyrockets_Inc Nov. 14 at 4:28 PM

$VYNE just wait, this will be the next $CYPH after we announce crypto treasury. Going to make a lot of people on this board rich. Holding 200k shares.

0 · Reply

Ericmao Nov. 14 at 9:45 AM

$VYNE let’s go today !!!!

1 · Reply

NEWYORKSILVERKING Nov. 14 at 3:04 AM

$VYNE Explain to me again why we have a CEO making over a million a year..... As of December 31, 2024, the Company had federal and state net operating loss carryforwards of $343.4 million and $53.6 million...As bad as those numbers are however, don`t they actually have some value in certain circumstances ??

1 · Reply

SmartMoneyTradez Nov. 13 at 10:35 PM

$GSIW $VYNE $GTBP 100% + plus runners when they break out

1 · Reply

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 3 months ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 3 months ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 4 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 7 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 7 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 8 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 9 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 9 months ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 9 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 11 months ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 11 months ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 2 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Dec 12, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

Dec 7, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Duskfall Nov. 14 at 8:48 PM

Yup $CHR $VYNE $OLB

1 · Reply

Lyn30 Nov. 14 at 6:04 PM

$VYNE Analyst pt $4 with with buy rating (1) High $6 and low $2.

1 · Reply

Lyn30 Nov. 14 at 5:52 PM

$VYNE Wide range resistance imo Around 2.25 is the resistance Anytime it can violent imo Cash/sh .98

0 · Reply

Lyn30 Nov. 14 at 5:22 PM

0 · Reply

CashtyNashty Nov. 14 at 5:21 PM

$VYNE cool chart. 😃

0 · Reply

hiTHit Nov. 14 at 4:52 PM

1 · Reply

skyrockets_Inc Nov. 14 at 4:28 PM

$VYNE just wait, this will be the next $CYPH after we announce crypto treasury. Going to make a lot of people on this board rich. Holding 200k shares.

0 · Reply

Ericmao Nov. 14 at 9:45 AM

$VYNE let’s go today !!!!

1 · Reply

NEWYORKSILVERKING Nov. 14 at 3:04 AM

1 · Reply

SmartMoneyTradez Nov. 13 at 10:35 PM

$GSIW $VYNE $GTBP 100% + plus runners when they break out

1 · Reply

Lyn30 Nov. 13 at 9:13 PM

$VYNE The list I made all ran except this one . May be it’s close 🚀🚀🚀🚀 Waiting for this one patiently . Let it go 1+

0 · Reply

Duskfall Nov. 13 at 8:48 PM

$VYNE 👍

1 · Reply

nonamestockz Nov. 13 at 8:47 PM

$VYNE now?

1 · Reply

Lyn30 Nov. 13 at 6:02 PM

$VYNE Just sell the company and give us 💰💰💰💰

0 · Reply

hiTHit Nov. 13 at 5:35 PM

$VYNE The 11,245 people here aren't writing on the board so that it won't be obvious they're laughing.🤓

1 · Reply

hiTHit Nov. 13 at 3:34 PM

$VYNE Be careful which board you spend your time on at StockTwits!

2 · Reply

CashtyNashty Nov. 13 at 12:55 PM

$VYNE read the DEF 14A posted last night. Subtle clues are telling of a big move coming. Just on topics pending for review that are super bullish: 1: asking for advisory compensation to NEOs 2: 💎💰To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. 3: No mention of a RS!!!!

1 · Reply

revuelto Nov. 13 at 12:07 AM

$VYNE strategic reviews unfortunately tend to take time.. months…hopefully for us the positive outcome comes sooner..maybe tomorrow….for now I’m stepping away from the board but my position stays unchanged…good luck everyone…hold the fort down for us 😀

0 · Reply

stonkmonkeys Nov. 12 at 6:59 PM

$VYNE soon

0 · Reply

hiTHit Nov. 12 at 3:24 PM

$VYNE If you don't tell real scammers that they are scammers, there will be no scammers left and your problems will be over.🤓

6 · Reply

CashtyNashty Nov. 12 at 3:12 PM

$VYNE

0 · Reply

Investor1337 Nov. 11 at 7:55 PM

$VYNE Hmmm interesting

0 · Reply

Market Cap	8.97M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	1,540,752
Avg Vol	2,330,594
Day's Range	N/A - N/A
Shares Out	25.47M
Stochastic %K	79%
Beta	1.95
Analysts	Sell
Price Target	$2.00